Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib (TAK-279) in Non-segmental Vitiligo – Phase II RCT
CTR20254990Phase 2Active
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zasocitinib in Vitiligo, sponsored by Takeda. Started Feb 2026; status: active.
02
Drugs
zasocitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20254990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254990.